Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2010

Open Access 01-12-2010 | Case report

Probable tacrolimus toxicity from tibolone co-administration in a woman: a case report

Authors: Carolyn J Clark, Carmel M Hawley, David W Mudge

Published in: Journal of Medical Case Reports | Issue 1/2010

Login to get access

Abstract

Introduction

Tibolone is a synthetic steroid, used with increasing frequency to treat symptoms of menopause, including patients with solid-organ transplants who are taking concurrent immune suppression. To the best of our knowledge, there are no reported drug interactions between tibolone and tacrolimus, one of the principal immune suppressants used in kidney transplantation.

Case presentation

We report the case of a 49-year-old Caucasian woman who had received a kidney transplant and who developed acute kidney injury secondary to tacrolimus toxicity 10 days after starting tibolone therapy. No alternative causes were found. Tibolone is known to be a weak competitive inhibitor of CYP3A4, which is involved in tacrolimus metabolism.

Conclusions

Despite a careful evaluation, no alternative reason was found for the acute kidney injury, and her kidney function returned to the previous baseline within several days of cessation of the medication, and with no other specific treatment. Using the Drug Interaction Probability Scale we conclude that she experienced a probable drug interaction. We believe that transplant clinicians should utilise frequent therapeutic drug monitoring of tacrolimus in patients starting or stopping tibolone therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Modelska K, Cummings S: Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 2002, 87: 16-23. 10.1210/jc.87.1.16.CrossRefPubMed Modelska K, Cummings S: Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab. 2002, 87: 16-23. 10.1210/jc.87.1.16.CrossRefPubMed
2.
go back to reference Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed
3.
go back to reference Kim N, Gross C, Curtis J, Stettin G, Wogen S, Choe N, Krumholz HM: The impact of clinical trials on the use of hormone replacement therapy: a population-based study. J Gen Intern Med. 2005, 20: 1026-1031. 10.1111/j.1525-1497.2005.0221.x.CrossRefPubMedPubMedCentral Kim N, Gross C, Curtis J, Stettin G, Wogen S, Choe N, Krumholz HM: The impact of clinical trials on the use of hormone replacement therapy: a population-based study. J Gen Intern Med. 2005, 20: 1026-1031. 10.1111/j.1525-1497.2005.0221.x.CrossRefPubMedPubMedCentral
4.
go back to reference Burger HG: Hormone therapy in the WHI era. Aust N Z J Obstet Gynaecol. 2006, 46: 84-91. 10.1111/j.1479-828X.2006.00533.x.CrossRefPubMed Burger HG: Hormone therapy in the WHI era. Aust N Z J Obstet Gynaecol. 2006, 46: 84-91. 10.1111/j.1479-828X.2006.00533.x.CrossRefPubMed
5.
go back to reference Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C: The effects of tibolone in older postmenopausal women. N Engl J Med. 2008, 359: 697-708. 10.1056/NEJMoa0800743.CrossRefPubMedPubMedCentral Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C: The effects of tibolone in older postmenopausal women. N Engl J Med. 2008, 359: 697-708. 10.1056/NEJMoa0800743.CrossRefPubMedPubMedCentral
6.
go back to reference Borrows R, Chusney G, Loucaidou M, Singh S, James A, Stichbury J, Van Tromp J, Cairns T, Griffith M, Hakim N: Tacrolimus monitoring in renal transplantation: a comparison between high-performance liquid chromatography and immunoassay. Transplant Proc. 2005, 37: 1733-1735. 10.1016/j.transproceed.2005.04.007.CrossRefPubMed Borrows R, Chusney G, Loucaidou M, Singh S, James A, Stichbury J, Van Tromp J, Cairns T, Griffith M, Hakim N: Tacrolimus monitoring in renal transplantation: a comparison between high-performance liquid chromatography and immunoassay. Transplant Proc. 2005, 37: 1733-1735. 10.1016/j.transproceed.2005.04.007.CrossRefPubMed
7.
go back to reference Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP: The in vivo human metabolism of tibolone. Drug Metab Dispos. 2002, 30: 106-112. 10.1124/dmd.30.2.106.CrossRefPubMed Vos RM, Krebbers SF, Verhoeven CH, Delbressine LP: The in vivo human metabolism of tibolone. Drug Metab Dispos. 2002, 30: 106-112. 10.1124/dmd.30.2.106.CrossRefPubMed
8.
go back to reference McLintock LA, Dykes A, Tait RC, Walker ID: Interaction between hormone replacement therapy preparations and oral anticoagulant therapy. BJOG. 2003, 110: 777-779. 10.1111/j.1471-0528.2003.02035.x.CrossRefPubMed McLintock LA, Dykes A, Tait RC, Walker ID: Interaction between hormone replacement therapy preparations and oral anticoagulant therapy. BJOG. 2003, 110: 777-779. 10.1111/j.1471-0528.2003.02035.x.CrossRefPubMed
9.
go back to reference Elbers J, Hageluken C, Wadham A: Tibolone (Livial) enhances warfarin-induced anticoagulation in postmenopausal women. Maturitas. 2007, 56: 94-100. 10.1016/j.maturitas.2006.06.010.CrossRefPubMed Elbers J, Hageluken C, Wadham A: Tibolone (Livial) enhances warfarin-induced anticoagulation in postmenopausal women. Maturitas. 2007, 56: 94-100. 10.1016/j.maturitas.2006.06.010.CrossRefPubMed
10.
go back to reference Horn JR, Hansten PD, Chan LN: Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007, 41: 674-680. 10.1345/aph.1H423.CrossRefPubMed Horn JR, Hansten PD, Chan LN: Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007, 41: 674-680. 10.1345/aph.1H423.CrossRefPubMed
Metadata
Title
Probable tacrolimus toxicity from tibolone co-administration in a woman: a case report
Authors
Carolyn J Clark
Carmel M Hawley
David W Mudge
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2010
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/1752-1947-4-276

Other articles of this Issue 1/2010

Journal of Medical Case Reports 1/2010 Go to the issue